Advertisement

Meta-Analysis of Adjuvant Chemotherapy Trials for Gastric Cancer at the Cancer Institute Hospital, Tokyo

  • Toshifusa Nakajima
  • Keiichiro Ohta
  • Shigekazu Ohyama
  • Nobuyuki Hamajima

Abstract

Despite a long history of clinical trials for adjuvant chemotherapy for gastric cancer, standard adjuvant chemotherapy is not yet established. Most Western trials produced no survival benefit with postoperative adjuvant chemotherapy [1], but there are a few encouraging reports from Japan [2, 3, 4]. The Japanese studies reported a marginal survival benefit in certain subsets, but it did not, as a whole, reach statistical significance. Failure to prove statistical significance is partly attributed to small sample size. Repeating a trial with encouraging but old regimens to confirm marginal efficacy is not a realistic solution: It is time-consuming and not attractive to clinical investigators. Meta-analysis may be, in such cases, an alternate approach to evaluating the clinical significance of previous trials of adjuvant chemotherapy.

Keywords

Gastric Cancer Adjuvant Chemotherapy Gastric Cancer Patient Cytosine Arabinoside Resectable Gastric Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Douglass HO Jr (1988) Western surgical adjuvant trials in gastric cancers: lessons from current trials to be applied to the future. In: Douglass HJ (ed) Gastric cancer. Churchill Livingstone, New York, pp 145–172Google Scholar
  2. 2.
    Nakajima T, Nishi M (1988) Adjuvant chemotherapy, immunochemotherapy, and neoadjuvant therapy for gastric cancer in Japan. In: Douglass HO Jr (ed) Gastric cancer. Churchill Livingstone, New York, pp 125–143Google Scholar
  3. 3.
    Nakajima T (1990) Adjuvant chemotherapy for gastric cancer in Japan: present status and suggestions for rational clinical trials. Jpn J Clin Oncol 20:30–42PubMedGoogle Scholar
  4. 4.
    Nakajima T (1995) Review of adjuvant chemotherapy for gastric cancer. World J Surg 19:570–574PubMedCrossRefGoogle Scholar
  5. 5.
    Nakajima T, Fukami A, Ohashi I, Kajitani T (1978) Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol 16:209–216Google Scholar
  6. 6.
    Nakajima T, Fukami A, Takagi K, Kajitani T (1980) Adjuvant chemotherapy with mitomycin C, and with a multidrug combination of mitomycin C, 5-fluorouracil and cytosine arabinoside after curative resection of gastric cancer. Jpn J Clin Oncol 10:187–194Google Scholar
  7. 7.
    Nakajima T (1991) Mitomycin C-based adjuvant chemotherapy in gastric cancer. In: Taguchi T, Aigner KR (eds) Mitomycin C in cancer chemotherapy today. Excerpta Medica, Amsterdam, pp 83–90Google Scholar
  8. 8.
    Nakajima T, Takahashi T, Takagi K, Kuno K, Kajitani T (1984) Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 2:1366–1371PubMedGoogle Scholar
  9. 9.
    Kleinbaum DG, Kupper LL, Morgenstern H (1982) Epidemiologic research, principles and quantitative methods, van Nostrand Reinhold, New YorkGoogle Scholar
  10. 10.
    Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMedGoogle Scholar
  11. 11.
    Yusuf S (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335–371PubMedCrossRefGoogle Scholar
  12. 12.
    DerSimonian D, Laird N (1986) Meta-analysis in clinical trials. Contemp Clin Trials 7:177–188CrossRefGoogle Scholar
  13. 13.
    Hermans J, Bonenkamp JJ, Boon MC, Bunt AMG, Ohyama S, Sasako M, Van de Velde CJH (1993) Adjuvant therapy after curative resection for gastric cancer: metaanalysis of randomized trials. J Clin Oncol 11:1441–1447PubMedGoogle Scholar
  14. 14.
    Pignon J, Decreux M, Rougier P (1994) Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. J Clin Oncol 12:877–878PubMedGoogle Scholar
  15. 15.
    Hermans J, Bonenkamp H (1994) In reply to the editor. J Clin Oncol 12:879–880Google Scholar
  16. 16.
    Hamajima N (1998) Basic technique for meta-analysis: calculation of summary statistic. J Jpn Assoc Cerebro-cardiovas Dis Control 33:266–271Google Scholar
  17. 17.
    Goldie J, Goldman A (1986) Theoretical considerations regarding the early use of adjuvant chemotherapy. Recent Results Cancer Res 103:30–35PubMedCrossRefGoogle Scholar
  18. 18.
    Doulgass HO Jr, Stablein D, Bruckner H, Moertel C, Livstone E, Kokich J, et al (1981) Randomized controlled trial by the gastrointestinal tumor study group (GITSG) of adjuvant chemotherapy (CT) of 5-fluorouracil (5FU) plus methyl-CCNU following curative resection for gastric carcinoma (CA). Proc Am Soc Clin Oncol 17:430Google Scholar
  19. 19.
    Allum WH, Halliscey MT, Ward LC, Hockey MS (1989) A controlled prospective, randomized trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. Br J Cancer 60:739–744PubMedCrossRefGoogle Scholar
  20. 20.
    Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duez N, Fiolentino M, Guimaraes JDS, Labianca R, Rougier P, Gignoux M (1995) Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 13:2757–2763PubMedGoogle Scholar
  21. 21.
    Dixon WJ, Longmire WP, Holden WD (1971) Use of tri-ethylenethiophosphamide as an adjuvant to the surgical treatment of gastric cancer and colorectal carcinoma: ten year follow up. Ann Surg 173:26–39PubMedCrossRefGoogle Scholar
  22. 22.
    Blokhina NG, Garin AM, Moroz LV, Pershin MP, Gunka II, Pantophel AM, Steklenev NA, Bashirova NG, Phateeva KV, Iunusmetov IR, Silitrin NP, Shklovskii GS, Balas AN, Ushivceva AE (1972) Treatment with 5-fluorouracil in prophylaxis of relapse and metastasis of stomach cancer. Neoplasma 19:351–356PubMedGoogle Scholar
  23. 23.
    Serlin O, Keehn R, Higgins G, Harrower H, Mendeloff G (1977) Factors related to survival following resection for gastric carcinoma: analysis of 903 cases. Cancer 40:1318–1328PubMedCrossRefGoogle Scholar
  24. 24.
    Hugier PF, Destroyes JP, Baschet C (1980) Gastric carcinoma treated by chemotherapy after resection. Am J Surg 139:197–199CrossRefGoogle Scholar
  25. 25.
    Engstrom PF, Lavin PT (1984) Adjuvant fluorouracil plus methyl-CCNU for resected gastric cancer: EST3275. In: Adjuvant therapy of cancer IV. Grune & Stratton, Orlando, pp 449–455Google Scholar
  26. 26.
    Krook JE, O’Connel MJ, Wieand HS, Beard RW Jr, Leigh JE, Kugler JW, Poley JF, Pfeifle DM, Twito DI (1991) A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 67:2454–2458PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 1999

Authors and Affiliations

  • Toshifusa Nakajima
    • 1
  • Keiichiro Ohta
    • 1
  • Shigekazu Ohyama
    • 1
  • Nobuyuki Hamajima
    • 2
  1. 1.Department of SurgeryCancer Institute HospitalTokyoJapan
  2. 2.Division of EpidemiologyAichi Cancer Center Research InstituteJapan

Personalised recommendations